Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India

Conclusion: EGFR/ALK co-alterations in adenocarcinomas albeit rare do exist. The challenge of monetary hurdle in developing countries with ALK TKI therapy can be handled by giving only EGFR TKI in these cases of concomitant mutations. Future perspective in research could be finding an agent with the potential of dual inhibition of ALK and EGFR.

Source: Journal of Cancer Research and Therapeutics - September 13, 2020 Category: Cancer & Oncology Authors: Prasanta Raghab Mohapatra Satyajeet Sahoo Sourin Bhuniya Manoj Kumar Panigrahi Saroj Kumar Das Majumdar Pritinanda Mishra Susama Patra Source Type: research